Clinical Trial

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-23; most recent amendment 2026-03-15.
Status change: Active, Not Recruiting → Recruiting 2026-03-15
Trial Details
NCT Number NCT06705062
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Conditions Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Enrollment 316 participants
Start Date 2025-01-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-17